marketcaparena
Search

    JAGX

    Jaguar Health, Inc.

    Company overview

    Market capitalization
    —
    Employees
    47
    Latest publication
    2026-09-29
    About Jaguar Health, Inc.

    Jaguar Health, Inc., a commercial-stage pharmaceuticals company, focuses on developing plant-based prescription medicines for people and animals with gastrointestinal distress. It operates through two segments, Animal Health and Human Health. The company focuses on developing and commercializing prescription and non-prescription products for companion and production animals; and human products. Its lead prescription drug is Mytesi, an anti-secretory antidiarrheal drug for the symptomatic relief of non-infectious diarrhea in adults with HIV/AIDS on antiretroviral therapy; and Canalevia-CA1, a prescription drug product for chemotherapy-induced diarrhea in dogs. It is also developing Crofelemer, an anti-secretory antidiarrheal drug, which is in Phase III clinical trial for prophylaxis of diarrhea in adult cancer patients; Phase II clinical trials for rare/orphan disease indications, including short bowel syndrome with intestinal failure and microvillus inclusion disease; diarrhea-predominant irritable bowel syndrome; and for idiopathic/functional diarrhea. In addition, the company is developing Mytesi which is in Phase III clinical trial for cancer therapy-related diarrhea, as well as Phase II clinical trial for irritable bowel syndrome; and NP-300, a second-generation antidiarrheal drug that is in Phase I clinical trial for symptomatic relief and treatment of moderate-to-severe diarrhea. The company is headquartered in San Francisco, California.

    Company website

    Financial statements

    Income Quarterly

    Exact reported values; units shown beside each amount. Missing values are —.
    MetricQ2 20262026-06-30 · USDQ1 20262026-03-31 · USDQ4 20252025-12-31 · USDQ3 20252025-09-30 · USDQ2 20252025-06-30 · USDQ1 20252025-03-31 · USDQ4 20242024-12-31 · USDQ3 20242024-09-30 · USD
    Total Revenue1,225,000USD20,272,000USD3,235,000USD3,083,000USD2,979,000USD2,214,000USD3,509,000USD3,108,000USD
    Cost Of Revenue1,031,000USD1,158,000USD2,200,000USD532,000USD527,000USD515,000USD557,000USD541,000USD
    Gross Profit194,000USD19,114,000USD1,035,000USD2,551,000USD2,452,000USD1,699,000USD2,952,000USD2,567,000USD
    Research Development3,336,000USD3,928,000USD14,313,000USD3,658,000USD3,265,000USD3,730,000USD4,534,000USD4,043,000USD
    Selling General Administrative4,450,000USD4,108,000USD5,306,000USD5,394,000USD6,160,000USD6,150,000USD5,033,000USD3,776,000USD
    Selling And Marketing Expenses5,000USD896,000USD—737,000USD1,034,000USD1,240,000USD1,542,000USD2,010,000USD
    General And Administrative Expenses4,450,000USD———————
    Total Operating Expenses7,791,000USD8,932,000USD23,677,000USD9,789,000USD10,459,000USD11,120,000USD11,109,000USD9,829,000USD
    Operating Income-7,597,000USD10,182,000USD-20,442,000USD-7,238,000USD-8,007,000USD-9,421,000USD-8,157,000USD-7,262,000USD
    Total Other Income Expense Net-5,205,000USD-1,459,000USD-2,619,000USD-2,410,000USD-2,553,000USD-1,175,000USD-2,077,000USD-2,759,000USD
    Interest Expense161,000USD699,000USD—6,000USD—56,000USD—162,000USD
    Income Before Tax-12,802,000USD8,723,000USD-23,193,000USD-9,648,000USD-10,560,000USD-10,596,000USD-10,234,000USD-10,021,000USD
    Income Tax Expense0USD15,738,000USD—-146,000USD—-132,000USD—-167,000USD
    Net Income-12,802,000USD8,849,000USD-23,061,000USD-9,502,000USD-10,407,000USD-10,464,000USD-9,920,000USD-9,854,000USD
    Minority Interest-120,000USD126,000USD132,000USD146,000USD153,000USD132,000USD314,000USD167,000USD
    Net Income Applicable To Common Shares-12,701,000USD———————
    Net Interest Income—-699,000USD-132,000USD-6,000USD15,000USD56,000USD110,000USD162,000USD
    Tax Provision—0USD0USD0USD0USD0USD0USD0USD
    Net Income From Continuing Ops—8,723,000USD-23,193,000USD-9,648,000USD-10,560,000USD-10,596,000USD-10,234,000USD-10,021,000USD
    Ebit—-29,264,000USD—-7,238,000USD-8,007,000USD-9,421,000USD-16,346,000USD-7,262,000USD
    Ebitda—8,723,000USD—-6,681,000USD-7,451,000USD-8,875,000USD-15,753,000USD-6,666,000USD
    Depreciation And Amortization—543,000USD—557,000USD556,000USD546,000USD593,000USD596,000USD
    Reconciled Depreciation—520,000USD543,000USD557,000USD556,000USD546,000USD593,000USD596,000USD
    Unclassified Operating Expenses——4,058,000USD—————
    Interest Income—————56,000USD——
    SourceDisclosureDeterministicFinalLegacy providerLegacyLegacy providerLegacyLegacy providerLegacyLegacy providerLegacyLegacy providerLegacyLegacy providerLegacyLegacy providerLegacy

    Income Yearly

    Exact reported values; units shown beside each amount. Missing values are —.
    MetricFY 20252025-12-31 · USDFY 20242024-12-31 · USDFY 20232023-12-31 · USDFY 20222022-12-31 · USDFY 20212021-12-31 · USDFY 20202020-12-31 · USDFY 20192019-12-31 · USDFY 20182018-12-31 · USD
    Total Revenue11,511,000USD11,689,000USD9,761,000USD11,956,000USD4,335,000USD9,385,000USD5,775,000USD4,416,145USD
    Cost Of Revenue3,774,000USD1,955,000USD2,037,000USD2,019,000USD2,333,000USD3,280,000USD3,816,000USD2,765,747USD
    Gross Profit7,737,000USD9,734,000USD7,724,000USD9,937,000USD2,002,000USD6,105,000USD1,959,000USD1,650,398USD
    Research Development24,966,000USD16,542,000USD18,596,000USD17,647,000USD15,079,000USD6,413,000USD5,820,000USD5,154,748USD
    Selling General Administrative18,644,000USD16,331,000USD16,588,000USD17,868,000USD17,103,000USD14,387,000USD13,502,000USD12,277,222USD
    Selling And Marketing Expenses9,235,000USD7,692,000USD6,460,000USD8,837,000USD8,894,000USD6,609,000USD6,936,000USD9,831,576USD
    Total Operating Expenses53,645,000USD40,565,000USD42,015,000USD44,352,000USD42,710,000USD32,752,000USD30,907,000USD27,263,546USD
    Operating Income-45,908,000USD-30,831,000USD-34,291,000USD-34,415,000USD-40,708,000USD-26,647,000USD-28,948,000USD-30,823,968USD
    Interest Expense67,000USD231,000USD6,382,000USD12,723,000USD8,421,000USD2,792,000USD5,731,000USD2,628,685USD
    Net Interest Income-67,000USD-231,000USD-8,768,000USD-12,723,000USD-10,055,000USD-8,135,000USD-5,730,648USD-2,628,685USD
    Income Before Tax-53,997,000USD-39,251,000USD-41,901,000USD-48,395,000USD-52,600,000USD-33,809,000USD-38,529,000USD-32,146,057USD
    Income Tax Expense-422,000USD-759,000USD-601,000USD-941,000USD7,651,000USD2,982,000USD10,000USD-1,275,540USD
    Tax Provision0USD0USD0USD0USD0USD0USD10,000USD0USD
    Net Income-53,575,000USD-38,492,000USD-41,300,000USD-47,454,000USD-52,595,000USD-33,809,000USD-38,539,000USD-32,146,057USD
    Net Income From Continuing Ops-53,997,000USD-39,251,000USD-40,824,000USD-48,395,000USD-52,600,000USD-33,809,000USD-38,539,436USD-32,146,057USD
    Ebit-37,895,000USD-39,020,000USD-33,920,000USD-35,672,000USD-44,179,000USD-31,017,000USD-32,798,000USD-29,517,373USD
    Ebitda-45,908,000USD-36,662,000USD-32,760,000USD-33,380,000USD-42,366,000USD-28,737,000USD-30,870,000USD-27,769,830USD
    Depreciation And Amortization-8,013,000USD2,358,000USD1,160,000USD2,292,000USD1,813,000USD2,280,000USD1,928,000USD1,747,543USD
    Reconciled Depreciation2,202,000USD2,358,000USD2,399,000USD2,292,000USD1,813,000USD2,280,000USD1,928,210USD1,319,003USD
    Total Other Income Expense Net-8,089,000USD-8,420,000USD-7,610,000USD-13,980,000USD-11,892,000USD-7,162,000USD-9,581,000USD-1,322,089USD
    Minority Interest563,000USD759,000USD1,113,000USD941,000USD5,000USD0USD——
    Unclassified Operating Expenses————1,634,000USD5,343,000USD4,649,000USD—
    Net Income Applicable To Common Shares————-52,595,000USD-38,648,000USD-32,352,630USD-32,146,057USD
    Non Operating Income Net Other—————-1,674,000USD-4,860,079USD-228,753USD
    Interest Income——————4,721,250USD2,297,670USD
    SourceLegacy providerLegacyLegacy providerLegacyLegacy providerLegacyLegacy providerLegacyLegacy providerLegacyLegacy providerLegacyLegacy providerLegacyLegacy providerLegacy

    Balance sheet Quarterly

    Exact reported values; units shown beside each amount. Missing values are —.
    MetricQ2 20262026-06-30 · USDQ1 20262026-03-31 · USDQ4 20252025-12-31 · USDQ3 20252025-09-30 · USDQ2 20252025-06-30 · USDQ1 20252025-03-31 · USDQ4 20242024-12-31 · USDQ3 20242024-09-30 · USD
    Total Assets34,194,000USD37,434,000USD38,323,000USD49,472,000USD48,268,000USD51,460,000USD53,425,000USD58,466,000USD
    Cash And Equivalents3,788,000USD———————
    Total Current Assets17,533,000USD20,210,000USD20,345,000USD29,402,000USD27,903,000USD30,439,000USD32,198,000USD36,643,000USD
    Other Current Assets3,429,000USD4,833,000USD2,216,000USD13,810,000USD13,661,000USD12,805,000USD12,204,000USD12,394,000USD
    Total Liabilities29,273,000USD———————
    Total Current Liabilities25,380,000USD40,686,000USD40,654,000USD36,122,000USD29,218,000USD28,208,000USD19,704,000USD19,874,000USD
    Other Current Liabilities4,712,000USD———————
    Total Equity Including Noncontrolling Interest4,921,000USD———————
    Deferred Revenue170,000USD———————
    Deferred Revenue Non Current298,000USD———————
    Net Receivables8,000USD280,000USD1,521,000USD1,437,000USD1,316,000USD1,389,000USD1,647,000USD1,306,000USD
    Inventory7,316,000USD7,819,000USD8,599,000USD10,628,000USD10,719,000USD10,555,000USD10,345,000USD9,674,000USD
    Property Plant Equipment Net1,428,000USD1,502,000USD1,463,000USD1,545,000USD1,579,000USD1,663,000USD1,400,000USD1,533,000USD
    Intangible Assets15,086,000USD15,553,000USD16,021,000USD17,285,000USD17,545,000USD18,011,000USD18,479,000USD18,947,000USD
    Accounts Payable4,793,000USD4,957,000USD8,686,000USD8,443,000USD6,617,000USD7,028,000USD5,286,000USD4,552,000USD
    Short Term Debt219,000USD31,808,000USD—23,334,000USD18,828,000USD18,909,000USD12,337,000USD11,855,000USD
    Retained Earnings-403,749,000USD-391,067,000USD-399,916,000USD-376,855,000USD-367,353,000USD-356,946,000USD-346,482,000USD-336,561,000USD
    Accumulated Other Comprehensive Income-1,241,000USD-1,242,000USD—-838,999USD-719,000USD-700,000USD-467,000USD-687,000USD
    Total Liab—53,186,000USD57,011,000USD45,113,000USD41,388,000USD50,630,000USD46,931,000USD45,368,000USD
    Total Stockholder Equity—-14,178,000USD-17,289,000USD5,627,000USD7,988,000USD1,782,000USD7,285,000USD13,612,000USD
    Other Current Liab—3,751,000USD—4,345,000USD3,603,000USD2,101,000USD1,797,000USD3,297,000USD
    Common Stock—1,000USD—————1,000USD
    Capital Stock—1,000USD2,486,000USD2,485,000USD2,485,000USD0USD0USD1,000USD
    Cash—7,278,000USD968,000USD3,527,000USD2,207,000USD5,690,000USD8,002,000USD13,269,000USD
    Cash And Short Term Investments—7,278,000USD—3,527,000USD2,207,000USD5,690,000USD8,002,000USD13,269,000USD
    Current Deferred Revenue—170,000USD—170,000USD170,000USD170,000USD170,000USD170,000USD
    Net Debt—27,033,000USD41,555,000USD28,373,000USD28,323,000USD32,646,000USD28,524,000USD21,000,000USD
    Short Long Term Debt—31,547,000USD27,440,000USD23,108,000USD18,572,000USD18,636,000USD12,038,000USD11,487,000USD
    Short Long Term Debt Total—34,311,000USD—31,900,000USD30,530,000USD38,336,000USD36,526,000USD34,269,000USD
    Long Term Debt—11,075,000USD15,083,000USD7,648,000USD10,742,000USD18,429,000USD23,503,000USD21,660,000USD
    Property Plant Equipment Gross—2,066,000USD2,021,000USD2,095,000USD2,115,000USD2,188,000USD1,913,000USD2,034,000USD
    Common Stock Shares Outstanding—515,795shares199,329shares43,233shares28,993shares17,904shares313,104shares10,709shares
    Non Current Assets Total—17,224,000USD17,978,000USD20,070,000USD20,365,000USD21,021,000USD21,227,000USD21,823,000USD
    Non Current Liabilities Total—12,500,000USD16,357,000USD8,991,000USD12,170,000USD22,422,000USD27,227,000USD25,494,000USD
    Non Currrent Assets Other—169,000USD494,000USD1,240,000USD1,241,000USD1,347,000USD1,348,000USD1,343,000USD
    Net Working Capital—-20,476,000USD-20,309,000USD-6,720,000USD-1,315,000USD2,231,000USD12,494,000USD16,769,000USD
    Unclassified Current Liabilities—-31,547,000USD4,528,000USD-23,278,000USD-18,572,000USD-18,636,000USD-11,924,000USD-11,487,000USD
    Unclassified Non Current Liabilities—1,425,000USD1,274,000USD1,343,000USD1,428,000USD3,993,000USD3,724,000USD3,834,000USD
    Unclassified Equity—378,129,000USD380,141,000USD380,835,999USD373,575,000USD359,428,000USD354,234,000USD350,858,000USD
    Unclassified Current Assets——7,041,000USD—————
    SourceDisclosureDeterministicFinalLegacy providerLegacyLegacy providerLegacyLegacy providerLegacyLegacy providerLegacyLegacy providerLegacyLegacy providerLegacyLegacy providerLegacy

    Balance sheet Yearly

    Exact reported values; units shown beside each amount. Missing values are —.
    MetricFY 20252025-12-31 · USDFY 20242024-12-31 · USDFY 20232023-12-31 · USDFY 20222022-12-31 · USDFY 20212021-12-31 · USDFY 20202020-12-31 · USDFY 20192019-12-31 · USDFY 20182018-12-31 · USD
    Total Assets38,323,000USD53,425,000USD50,763,000USD47,452,000USD53,265,000USD42,843,000USD36,410,000USD41,041,945USD
    Intangible Assets16,021,000USD18,479,000USD20,116,000USD22,439,000USD22,651,000USD24,337,000USD26,024,000USD31,710,556USD
    Other Current Assets9,080,000USD12,204,000USD10,121,000USD7,361,000USD4,339,000USD2,360,000USD2,204,000USD1,243,890USD
    Total Liab57,011,000USD46,931,000USD45,866,000USD48,808,000USD41,412,000USD25,641,000USD25,737,000USD35,658,824USD
    Total Stockholder Equity-17,289,000USD7,285,000USD4,961,000USD-657,000USD11,611,000USD17,202,000USD10,673,000USD5,383,121USD
    Other Current Liab4,166,000USD1,797,000USD3,506,000USD7,580,000USD6,608,000USD4,545,000USD2,684,000USD5,006,361USD
    Common Stock1,000USD—7,000USD—5,000USD4,000USD5,000USD6,490USD
    Capital Stock2,486,000USD0USD7,000USD0USD5,000USD11,000USD1,717,450USD6,490USD
    Retained Earnings-399,916,000USD-346,482,000USD-308,249,000USD-266,948,000USD-219,494,000USD-166,899,000USD-133,090,000USD-94,550,779USD
    Cash968,000USD8,002,000USD6,469,000USD5,469,000USD17,051,000USD8,090,000USD3,495,000USD2,568,191USD
    Cash And Short Term Investments968,000USD8,002,000USD6,469,000USD5,469,000USD17,051,000USD8,090,000USD3,495,000USD2,568,191USD
    Total Current Assets20,345,000USD32,198,000USD27,963,000USD22,321,000USD28,434,000USD17,792,000USD9,522,000USD8,149,941USD
    Total Current Liabilities40,654,000USD19,704,000USD13,987,000USD30,339,000USD15,471,000USD13,220,000USD15,392,000USD26,658,822USD
    Current Deferred Revenue170,000USD170,000USD——7,117,000USD4,493,000USD2,922,255USD4,939,441USD
    Net Debt42,639,000USD28,524,000USD30,625,000USD29,366,000USD12,314,000USD8,120,000USD4,070,000USD13,516,554USD
    Short Term Debt27,632,000USD12,337,000USD5,215,000USD16,366,000USD3,424,000USD3,789,000USD7,115,000USD16,084,745USD
    Short Long Term Debt27,440,000USD12,038,000USD4,867,000USD15,883,000USD3,184,000USD3,789,000USD6,778,461USD16,084,745USD
    Short Long Term Debt Total43,607,000USD36,526,000USD37,094,000USD34,835,000USD29,365,000USD16,210,000USD7,565,000USD16,084,745USD
    Long Term Debt15,083,000USD23,503,000USD30,993,000USD17,744,000USD25,022,000USD12,421,000USD450,000USD—
    Net Receivables1,698,000USD1,647,000USD2,184,000USD2,467,000USD2,144,000USD4,560,000USD1,694,000USD1,001,801USD
    Inventory8,599,000USD10,345,000USD9,189,000USD7,024,000USD4,900,000USD2,782,000USD2,129,000USD3,342,177USD
    Accounts Payable8,686,000USD5,286,000USD4,974,000USD5,808,000USD4,929,000USD4,759,000USD5,352,000USD5,414,260USD
    Property Plant Equipment Net1,463,000USD1,400,000USD1,672,000USD1,697,000USD1,734,000USD677,000USD710,000USD760,617USD
    Property Plant Equipment Gross2,021,000USD1,913,000USD2,137,000USD2,101,000USD2,032,000USD677,000USD710,207USD760,617USD
    Accumulated Other Comprehensive Income-833,000USD-467,000USD-652,000USD-680,000USD—-42,843,000USD-224,069USD-9,000,002,000,000USD
    Common Stock Shares Outstanding66,640shares8,415shares439shares25shares5shares1shares0shares0shares
    Non Current Assets Total17,978,000USD21,227,000USD22,800,000USD25,131,000USD24,831,000USD25,051,000USD26,888,000USD32,892,004USD
    Non Current Liabilities Total16,357,000USD27,227,000USD31,879,000USD18,469,000USD25,941,000USD12,421,000USD10,345,000USD9,000,002USD
    Non Currrent Assets Other494,000USD1,348,000USD1,012,000USD995,000USD446,000USD37,000USD154,000USD420,831USD
    Net Working Capital-20,309,000USD12,494,000USD13,976,000USD-8,018,000USD12,963,000USD4,572,000USD-5,870,038USD-18,508,881USD
    Unclassified Current Liabilities-27,440,000USD-11,924,000USD-4,575,000USD-15,298,000USD-9,791,000USD-8,155,000USD-9,459,716USD-20,870,730USD
    Unclassified Non Current Liabilities1,274,000USD3,724,000USD————9,895,000USD9,000,002USD
    Unclassified Equity380,973,000USD354,234,000USD313,848,000USD266,971,000USD231,095,000USD226,929,000USD142,264,619USD9,000,101,920,920USD
    Other Assets——1USD—446,000USD37,000USD153,973USD420,831USD
    Net Tangible Assets————-11,040,000USD-7,135,000USD-7,167,850USD-17,327,433USD
    Good Will———————0USD
    SourceLegacy providerLegacyLegacy providerLegacyLegacy providerLegacyLegacy providerLegacyLegacy providerLegacyLegacy providerLegacyLegacy providerLegacyLegacy providerLegacy

    Cash flow YTD

    Exact reported values; units shown beside each amount. Missing values are —.
    MetricQ2 20262026-06-30 · USD
    Depreciation946,000USD
    Stock Based Compensation326,000USD
    Other Non Cash Items-4,132,000USD
    Change To Account Receivables1,513,000USD
    Change To Inventory1,283,000USD
    Change To Liabilities-2,914,000USD
    Change In Working Capital-980,000USD
    Operating Cash Flow3,492,000USD
    Financing Cash Flow-4,753,000USD
    Effect Of Forex Changes On Cash19,000USD
    Change In Cash-1,242,000USD
    End Cash Flow6,590,000USD
    SourceDisclosureDeterministicFinal

    Cash flow Quarterly

    Exact reported values; units shown beside each amount. Missing values are —.
    MetricQ1 20262026-03-31 · USDQ4 20252025-12-31 · USDQ3 20252025-09-30 · USDQ2 20252025-06-30 · USDQ1 20252025-03-31 · USDQ4 20242024-12-31 · USDQ3 20242024-09-30 · USDQ2 20242024-06-30 · USD
    Net Income8,265,000USD-23,061,000USD-9,502,000USD-10,583,000USD-10,464,000USD-9,977,000USD-10,339,000USD-9,721,000USD
    Depreciation520,000USD543,000USD560,000USD556,000USD546,000USD593,000USD596,000USD559,000USD
    Stock Based Compensation155,000USD116,000USD135,000USD279,000USD301,000USD372,000USD305,000USD383,000USD
    Other Non Cash Items1,231,000USD—2,208,000USD2,932,000USD982,000USD2,625,000USD1,704,000USD1,849,000USD
    Change To Account Receivables1,416,000USD-84,000USD-188,000USD82,000USD259,000USD-352,000USD-96,000USD349,000USD
    Change To Inventory780,000USD29,000USD91,000USD-165,000USD-209,000USD-671,000USD-118,000USD-536,000USD
    Change In Working Capital-1,341,000USD12,522,000USD2,045,000USD623,000USD1,319,000USD-1,439,000USD1,393,000USD-1,240,000USD
    Total Cash From Operating Activities8,830,000USD-5,488,000USD-4,689,000USD-6,193,000USD-7,316,000USD-7,826,000USD-6,341,000USD-8,170,000USD
    Capital Expenditures-29,000USD0USD-54,000USD0USD-215,000USD-215,000USD-16,000USD-16,000USD
    Free Cash Flow8,830,000USD-5,475,000USD-4,743,000USD-6,193,000USD-7,316,000USD-8,041,000USD-6,325,000USD-8,186,000USD
    Total Cashflows From Investing Activities13,000USD—-54,000USD—-215,000USD——-16,000USD
    Net Borrowings-6,615,000USD9,830,000USD283,000USD-148,000USD3,210,000USD0USD216,000USD—
    Total Cash From Financing Activities-6,615,000USD9,790,000USD6,259,000USD2,655,000USD4,966,000USD2,830,000USD3,530,000USD12,574,000USD
    Sale Purchase Of Stock-31,066,000USD———————
    Issuance Of Capital Stock0USD-40,000USD6,458,000USD2,803,000USD1,756,000USD3,001,000USD3,751,000USD12,668,000USD
    Change In Cash2,232,000USD4,305,000USD1,320,000USD-3,481,000USD-2,314,000USD-5,267,000USD-2,780,000USD4,378,000USD
    Begin Period Cash Flow7,832,000USD3,527,000USD2,207,000USD5,688,000USD8,002,000USD13,269,000USD16,049,000USD11,671,000USD
    End Period Cash Flow10,064,000USD7,832,000USD3,527,000USD2,207,000USD5,688,000USD8,002,000USD13,269,000USD16,049,000USD
    Other Cashflows From Investing Activities-16,000USD—-54,000USD————-16,000USD
    Other Cashflows From Financing Activities72,478,000USD—6,259,000USD1,309,000USD-171,000USD-171,000USD-437,000USD12,574,000USD
    Unclassified Financing Cash Flow-41,412,000USD—-6,741,000USD-1,309,000USD———-12,668,000USD
    Unclassified Operating Cash Flow—4,392,000USD——————
    Investments——-54,000USD——-215,000USD0USD—
    SourceLegacy providerLegacyLegacy providerLegacyLegacy providerLegacyLegacy providerLegacyLegacy providerLegacyLegacy providerLegacyLegacy providerLegacyLegacy providerLegacy

    Cash flow Yearly

    Exact reported values; units shown beside each amount. Missing values are —.
    MetricFY 20252025-12-31 · USDFY 20242024-12-31 · USDFY 20232023-12-31 · USDFY 20222022-12-31 · USDFY 20212021-12-31 · USDFY 20202020-12-31 · USDFY 20192019-12-31 · USDFY 20182018-12-31 · USD
    Net Income-15,374,000USD-39,034,000USD-41,870,000USD-49,075,000USD-52,600,000USD-33,809,000USD-38,539,000USD-32,146,057USD
    Depreciation3,000USD2,358,000USD2,388,000USD2,292,000USD1,813,000USD2,280,000USD1,928,000USD1,319,003USD
    Stock Based Compensation-810,000USD1,641,000USD2,112,000USD3,318,000USD3,974,000USD2,824,000USD2,989,000USD2,023,874USD
    Other Non Cash Items9,088,000USD8,661,000USD15,227,000USD14,789,000USD5,187,000USD6,572,000USD13,827,000USD1,248,507USD
    Change To Account Receivables-434,000USD526,000USD298,000USD-170,000USD2,823,000USD-2,840,000USD-704,000USD-528,025USD
    Change To Inventory902,000USD-1,156,000USD-2,165,000USD-2,124,000USD-2,118,000USD-653,000USD1,213,000USD-1,269,360USD
    Change In Working Capital12,891,000USD-3,010,000USD-11,099,000USD-4,428,000USD2,267,000USD-3,467,000USD-662,000USD-925,099USD
    Total Cash From Operating Activities5,798,000USD-29,384,000USD-33,242,000USD-33,104,000USD-34,970,000USD-15,278,000USD-20,457,000USD-22,730,832USD
    Capital Expenditures-25,000USD-231,000USD0USD-1,675,000USD-6,000USD-7,000USD-7,000USD-6,527USD
    Free Cash Flow5,773,000USD-29,615,000USD-33,242,000USD-34,779,000USD-34,976,000USD-15,285,000USD-20,457,000USD-22,737,359USD
    Total Cashflows From Investing Activities149,000USD-231,000USD1,233,000USD-1,675,000USD-6,000USD-7,000USD-7,000USD-6,527USD
    Net Borrowings13,345,000USD-100,000USD-100,000USD3,875,000USD8,110,000USD12,063,000USD-100,000USD1,349,738USD
    Total Cash From Financing Activities-44,331,000USD31,202,000USD34,227,000USD23,181,000USD43,937,000USD19,492,000USD21,772,000USD24,545,683USD
    Sale Purchase Of Stock-31,066,000USD————33,000USD3,075,523USD-30USD
    Issuance Of Capital Stock10,977,000USD31,910,000USD24,134,000USD20,462,000USD33,578,000USD1,949,000USD12,645,770USD25,879,774USD
    Change In Cash-38,353,000USD1,533,000USD1,000,000USD-11,582,000USD8,961,000USD4,207,000USD1,315,000USD1,808,324USD
    Begin Period Cash Flow46,185,000USD6,469,000USD5,469,000USD17,051,000USD8,090,000USD3,883,000USD2,568,000USD759,867USD
    End Period Cash Flow7,832,000USD8,002,000USD6,469,000USD5,469,000USD17,051,000USD8,090,000USD3,883,000USD2,568,191USD
    Other Cashflows From Investing Activities174,000USD-215,000USD—-1,598,000USD-247,000USD-7,000USD—-6,527,000,000USD
    Other Cashflows From Financing Activities5,786,000USD-608,000USD2,227,000USD-1,156,000USD1,306,000USD18,630,000USD15,245,000USD7,081,452USD
    Unclassified Financing Cash Flow-32,396,000USD—7,966,000USD——-11,201,000USD3,551,477USD28,352,463USD
    Investments—-231,000USD-361,000USD-1,675,000USD-6,000USD-7,000USD-7,000USD-6,527USD
    Unclassified Investing Cash Flow——1,594,000USD3,273,000USD———6,527,006,527USD
    Change To Liabilities————158,000USD-743,000USD-1,122,121USD1,319,448USD
    Unclassified Operating Cash Flow————4,389,000USD10,322,000USD—5,748,940USD
    Dividends Paid—————-33,000USD—-12,237,940USD
    Cash And Cash Equivalents Changes—————4,207,000USD1,315,187USD1,808,324USD
    SourceLegacy providerLegacyLegacy providerLegacyLegacy providerLegacyLegacy providerLegacyLegacy providerLegacyLegacy providerLegacyLegacy providerLegacyLegacy providerLegacy

    Operating metrics

    No operating metrics are currently published for this company.

    Revenue breakdown

    PeriodDimensionBusiness / regionRevenueCurrencySource
    Q1 2026Quarterly · 2026-03-31ProductGrant25,000USD0001193125-26-232560
    Q1 2026Quarterly · 2026-03-31ProductLicense19,000,000USD0001193125-26-232560
    Q1 2026Quarterly · 2026-03-31ProductOther43,000USD0001193125-26-232560
    Q1 2026Quarterly · 2026-03-31ProductProduct1,204,000USD0001193125-26-232560
    Q1 2026Quarterly · 2026-03-31SegmentAnimal Health345,000USD0001193125-26-232560
    Q1 2026Quarterly · 2026-03-31SegmentHuman Health19,927,000USD0001193125-26-232560
    Q4 2025Quarterly · 2025-12-31ProductCanalevia39,000USDLegacy provider
    Q4 2025Quarterly · 2025-12-31ProductMytesi3,100,000USDLegacy provider
    Q4 2025Quarterly · 2025-12-31ProductNeonorm1,000USDLegacy provider
    Q4 2025Quarterly · 2025-12-31ProductOther95,000USDLegacy provider
    Q4 2025Quarterly · 2025-12-31SegmentAnimal Health83,000USDLegacy provider
    Q4 2025Quarterly · 2025-12-31SegmentHuman Health3,152,000USDLegacy provider
    FY 2025Yearly · 2025-12-31ProductCanalevia148,000USD0001193125-26-144470
    FY 2025Yearly · 2025-12-31ProductMytesi11,000,000USD0001193125-26-144470
    FY 2025Yearly · 2025-12-31ProductNeonorm35,000USD0001193125-26-144470
    FY 2025Yearly · 2025-12-31ProductOther328,000USD0001193125-26-144470
    FY 2025Yearly · 2025-12-31SegmentAnimal Health353,000USD0001193125-26-144470
    FY 2025Yearly · 2025-12-31SegmentHuman Health11,158,000USD0001193125-26-144470
    Q3 2025Quarterly · 2025-09-30ProductCanalevia32,000USD0001193125-25-282950
    Q3 2025Quarterly · 2025-09-30ProductMytesi3,000,000USD0001193125-25-282950
    Q3 2025Quarterly · 2025-09-30ProductNeonorm4,000USD0001193125-25-282950
    Q3 2025Quarterly · 2025-09-30ProductOther47,000USD0001193125-25-282950
    Q3 2025Quarterly · 2025-09-30SegmentAnimal Health78,000USD0001193125-25-282950
    Q3 2025Quarterly · 2025-09-30SegmentHuman Health3,005,000USD0001193125-25-282950
    Q2 2025Quarterly · 2025-06-30ProductCanalevia60,000USD0000950170-25-108393
    Q2 2025Quarterly · 2025-06-30ProductMytesi2,800,000USD0000950170-25-108393
    Q2 2025Quarterly · 2025-06-30ProductNeonorm14,000USD0000950170-25-108393
    Q2 2025Quarterly · 2025-06-30ProductOther105,000USD0000950170-25-108393
    Q2 2025Quarterly · 2025-06-30SegmentAnimal Health116,000USD0000950170-25-108393
    Q2 2025Quarterly · 2025-06-30SegmentHuman Health2,863,000USD0000950170-25-108393
    Q1 2025Quarterly · 2025-03-31ProductCanalevia17,000USD0001193125-26-232560
    Q1 2025Quarterly · 2025-03-31ProductMytesi2,100,000USD0001193125-26-232560
    Q1 2025Quarterly · 2025-03-31ProductNeonorm16,000USD0001193125-26-232560
    Q1 2025Quarterly · 2025-03-31ProductOther81,000USD0001193125-26-232560
    Q1 2025Quarterly · 2025-03-31SegmentAnimal Health76,000USD0001193125-26-232560
    Q1 2025Quarterly · 2025-03-31SegmentHuman Health2,138,000USD0001193125-26-232560
    Q4 2024Quarterly · 2024-12-31SegmentAnimal Health89,000USDLegacy provider
    Q4 2024Quarterly · 2024-12-31SegmentHuman Health3,420,000USDLegacy provider
    FY 2024Yearly · 2024-12-31ProductCanalevia160,000USD0001193125-26-144470
    FY 2024Yearly · 2024-12-31ProductMytesi11,300,000USD0001193125-26-144470
    FY 2024Yearly · 2024-12-31ProductNeonorm28,000USD0001193125-26-144470
    FY 2024Yearly · 2024-12-31ProductOther201,000USD0001193125-26-144470
    FY 2024Yearly · 2024-12-31SegmentAnimal Health315,000USD0001193125-26-144470
    FY 2024Yearly · 2024-12-31SegmentHuman Health11,374,000USD0001193125-26-144470
    Q3 2024Quarterly · 2024-09-30ProductCanalevia49,000USD0001193125-25-282950
    Q3 2024Quarterly · 2024-09-30ProductMytesi3,000,000USD0001193125-25-282950
    Q3 2024Quarterly · 2024-09-30ProductNeonorm4,000USD0001193125-25-282950
    Q3 2024Quarterly · 2024-09-30ProductOther55,000USD0001193125-25-282950
    Q3 2024Quarterly · 2024-09-30SegmentAnimal Health94,000USD0001193125-25-282950
    Q3 2024Quarterly · 2024-09-30SegmentHuman Health3,014,000USD0001193125-25-282950
    Q2 2024Quarterly · 2024-06-30ProductCanalevia26,000USD0000950170-25-108393
    Q2 2024Quarterly · 2024-06-30ProductMytesi2,700,000USD0000950170-25-108393
    Q2 2024Quarterly · 2024-06-30ProductNeonorm15,000USD0000950170-25-108393
    Q2 2024Quarterly · 2024-06-30SegmentAnimal Health84,000USD0000950170-25-108393
    Q2 2024Quarterly · 2024-06-30SegmentHuman Health2,637,000USD0000950170-25-108393
    Q1 2024Quarterly · 2024-03-31ProductCanalevia40,000USD0000950170-25-072367
    Q1 2024Quarterly · 2024-03-31ProductMytesi2,300,000USD0000950170-25-072367
    Q1 2024Quarterly · 2024-03-31ProductNeonorm9,000USD0000950170-25-072367
    FY 2023Yearly · 2023-12-31ProductCanalevia130,000USD0000950170-25-047184
    FY 2023Yearly · 2023-12-31ProductMytesi9,600,000USD0000950170-25-047184
    FY 2023Yearly · 2023-12-31ProductNeonorm42,000USD0000950170-25-047184
    FY 2023Yearly · 2023-12-31SegmentAnimal Health173,000USD0000950170-25-047184
    FY 2023Yearly · 2023-12-31SegmentHuman Health9,588,000USD0000950170-25-047184
    FY 2021Yearly · 2021-12-31ProductCanalevia0USD0001558370-23-004572
    FY 2021Yearly · 2021-12-31ProductMytesi4,300,000USD0001558370-23-004572
    FY 2021Yearly · 2021-12-31ProductNeonorm62,000USD0001558370-23-004572
    FY 2019Yearly · 2019-12-31ProductMytesi5,700,000USD0001558370-21-003811
    FY 2019Yearly · 2019-12-31ProductNeonorm102,000USD0001558370-21-003811
    FY 2018Yearly · 2018-12-31ProductBotanical Extract0USD0001558370-19-002908
    FY 2018Yearly · 2018-12-31ProductMytesi4,121,913USD0001558370-19-002908
    FY 2018Yearly · 2018-12-31ProductNeonorm116,843USD0001558370-19-002908
    FY 2018Yearly · 2018-12-31ProductOther177,389USD0001558370-19-002908
    FY 2018Yearly · 2018-12-31SegmentAnimal Health294,232USD0001558370-19-002908
    FY 2018Yearly · 2018-12-31SegmentHuman Health4,121,913USD0001558370-19-002908
    FY 2017Yearly · 2017-12-31ProductCollaboration2,876,072USD0001558370-19-002908
    FY 2017Yearly · 2017-12-31ProductProduct1,485,114USD0001558370-19-002908
    FY 2017Yearly · 2017-12-31SegmentAnimal Health3,298,266USD0001558370-19-002908
    FY 2017Yearly · 2017-12-31SegmentHuman Health1,062,920USD0001558370-19-002908

    Periods follow company fiscal calendars. Quarterly, annual and year-to-date amounts are shown separately. Missing values are not zero. Data may be delayed, incomplete or corrected; follow the disclosure links to verify figures.